Description
Artogistan Pharmacodynamics
It has a chondrostimulating, regenerating, anti-inflammatory and analgesic effect. Chondroitin sulfate is involved in the construction of the basic substance of cartilage and bone tissue. It has chondroprotective properties, enhances metabolic processes in hyaline and fibrous cartilage, subchondral bone, inhibits enzymes that cause degeneration (destruction) of articular cartilage, stimulates the production of chondrocytes proteoglycans. Helps reduce the release into the synovial fluid of inflammatory mediators and pain factors, inhibits the secretion of leukotrienes and prostaglandins. Slows bone resorption and reduces calcium loss, speeds up bone repair processes.
Chondroitin sulfate slows the progression of osteoarthritis and osteochondrosis. Helps restore the joint capsule and cartilage surfaces of joints, prevents collapse of connective tissue, and normalizes the production of joint fluid.
The use of the drug reduces pain and improves mobility of affected joints, while the therapeutic effect lasts for a long time after the end of therapy. In the treatment of degenerative changes in the joints, accompanied by secondary synovitis, the effect is observed in 2-3 weeks from the start of the course.
Having structural similarity with heparin, it can potentially prevent the formation of fibrin clots in the synovial and subchondral microcirculatory channel.
Indications
Degenerative-dystrophic diseases of the joints and spine: osteoarthritis and spinal osteochondrosis.
To accelerate the formation of the bone callus on fractures.
Contraindications .
– Hypersensitivity to the drug or its components;
– Bleeding, a tendency to bleeding;
– thrombophlebitis;
– Children under 18 years of age (efficacy and safety have not been established).
Caution:
No data.
Pregnancy and lactation:
It is not recommended to use the drug in pregnancy. During treatment, breast-feeding should be discontinued due to lack of data.
Dosage and administration method
- Intramuscularly, 100 mg every other day. If tolerated, the dose is increased to 200 mg, starting with the fourth injection. The course of treatment is 25-35 injections. If necessary, a second course of treatment may be carried out after 6 months.
